|
|
|
|
|
|
|
M Tue W Th F |
|
18 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Ryan Cross reveals that a man in his 50s died earlier this year in a Chinese investigator-initiated trial, marking the third such death reported in recent weeks. Read on for details. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Ryan Cross
|
A patient with an autoimmune disease has died after receiving an experimental genetic medicine from a biotech startup in China, Endpoints News has learned. The... | |
|
|
|
|
|
|
by Kyle LaHucik
|
A week after ending developmentof a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very... | |
|
|
|
|
|
 |
|
Amylyx co-CEOs Justin Klee (L) and Joshua Cohen |
|
|
|
by Max Gelman
|
After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech. A... | |
|
|
|
 |
|
Christophe Bourdon, Leo Pharma CEO |
|
|
|
by Ayisha Sharma
|
Leo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a... | |
|
|
|
|
|
